When should I use the CISNE Score?

Use the CISNE Score when you need a structured infectious-disease assessment to support bedside triage, escalation, or follow-up decisions. It should complement, not replace, clinical judgement and local guideline pathways.

Does the CISNE Score replace specialist review?

No. The CISNE Score helps standardize risk assessment and communication, but specialist input, microbiology data, imaging, and patient trajectory still drive final management.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

CISNE Score

CISNE Score: Prognostic model for seemingly stable solid tumor patients with febrile neutropenia. Identifies patients safe for outpatient management.

CISNE Score

0

Risk Assessment

Low Risk

1.1% Complication Risk

Low-risk profile. Potential candidate for outpatient management with oral antibiotics.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Clinical Use

The Clinical Index of Stable Febrile Neutropenia (CISNE) score is used to identify low-risk patients with solid tumors who present with febrile neutropenia but are clinically stable.

Target Population

Specifically validated for patients with solid tumors. For hematologic malignancies, the MASCC score is typically preferred.

Section 2

Formula & Logic

Scoring Components

Criterion	Points
ECOG Performance Status ≥ 2	2
Stress-induced hyperglycemia	2
COPD	1
Chronic cardiovascular disease	1
Mucositis (Grade ≥ 2)	1
Monocytes < 200/µL	1

Section 3

Pearls/Pitfalls

Risk Groups

Score	Risk Group	Risk of Complications
0	Low Risk	1.1%
1 - 2	Intermediate Risk	6.2%
≥ 3	High Risk	36%

Section 4

Evidence Appraisal

Primary Reference

Prediction of serious complications in patients with seemingly stable febrile neutropenia: the CISNE model

Carmona-Bayonas A et al. • Journal of Clinical Oncology. 2015;33(5):465-71

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Clinical Use

The Clinical Index of Stable Febrile Neutropenia (CISNE) score is used to identify low-risk patients with solid tumors who present with febrile neutropenia but are clinically stable.

Target Population

Specifically validated for patients with solid tumors. For hematologic malignancies, the MASCC score is typically preferred.

Section 2

Formula & Logic

Scoring Components

Criterion	Points
ECOG Performance Status ≥ 2	2
Stress-induced hyperglycemia	2
COPD	1
Chronic cardiovascular disease	1
Mucositis (Grade ≥ 2)	1
Monocytes < 200/µL	1

Section 3

Pearls/Pitfalls

Risk Groups

Score	Risk Group	Risk of Complications
0	Low Risk	1.1%
1 - 2	Intermediate Risk	6.2%
≥ 3	High Risk	36%

Section 4

Evidence Appraisal

Primary Reference

Prediction of serious complications in patients with seemingly stable febrile neutropenia: the CISNE model

Carmona-Bayonas A et al. • Journal of Clinical Oncology. 2015;33(5):465-71

Last Comprehensive Review: 2026

Related Hematology Tools

Perioperative Anticoagulation Bridging

Time in Therapeutic Range

Fibrinogen Replacement

Blood Volume Calculator

Expected Hb Rise per RBC Unit

Platelet Increment Calculator

TACO Risk Score

MTP Activation Criteria

ABC Score

Febrile Neutropaenia Risk

Have feedback about this calculator?Let us know.

CISNE Score

CISNE Score: Prognostic model for seemingly stable solid tumor patients with febrile neutropenia. Identifies patients safe for outpatient management.

CISNE Score

0

Risk Assessment

Low Risk

1.1% Complication Risk

Low-risk profile. Potential candidate for outpatient management with oral antibiotics.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Clinical Use

The Clinical Index of Stable Febrile Neutropenia (CISNE) score is used to identify low-risk patients with solid tumors who present with febrile neutropenia but are clinically stable.

Target Population

Specifically validated for patients with solid tumors. For hematologic malignancies, the MASCC score is typically preferred.

Section 2

Formula & Logic

Scoring Components

Criterion	Points
ECOG Performance Status ≥ 2	2
Stress-induced hyperglycemia	2
COPD	1
Chronic cardiovascular disease	1
Mucositis (Grade ≥ 2)	1
Monocytes < 200/µL	1

Section 3

Pearls/Pitfalls

Risk Groups

Score	Risk Group	Risk of Complications
0	Low Risk	1.1%
1 - 2	Intermediate Risk	6.2%
≥ 3	High Risk	36%

Section 4

Evidence Appraisal

Primary Reference

Prediction of serious complications in patients with seemingly stable febrile neutropenia: the CISNE model

Carmona-Bayonas A et al. • Journal of Clinical Oncology. 2015;33(5):465-71

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Clinical Use

The Clinical Index of Stable Febrile Neutropenia (CISNE) score is used to identify low-risk patients with solid tumors who present with febrile neutropenia but are clinically stable.